Tirzepatide Price Per Milligram

The arithmetic

A month is four weekly injections. At 2.5 mg that is 10 mg of active drug; at 10 mg it is 40 mg; at the ceiling, 60 mg. Dividing the all-in monthly price by milligrams delivered removes the dose from the comparison entirely.

Where per-milligram misleads

It ignores what is bundled. A programme including clinician access, laboratory work and responsive support is not comparable per milligram to one that ships a vial. Use it as one lens rather than the only one.

Why nobody advertises this number

Because it makes the starter-dose discount disappear. A programme whose entry price looks generous frequently has the worst per-milligram figure at initiation, and the advertised number is chosen precisely because that comparison is not being made.

What the spread tells you

All-in cost at a 10 mg maintenance dose runs from $215 to $597 across the 16 programmes we price. That is the identical molecule from the same category of licensed pharmacy, so the difference is overhead, clinical wrap, sourcing and margin rather than the medicine.

A 2.8-times spread on an identical product is unusual outside markets where buyers cannot easily compare, which is exactly the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 2.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free, takes about two minutes, and fewer than a fifth of priced programmes publish enough to let you do it.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 10 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices captured 2026-08-05. Every figure on this page carries that date and an evidence status saying whether we read it at the provider or took it from a third party. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded tirzepatide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

Reading this against the rest of the market

The programmes named above sit inside a market where 16 routes publish a price we could capture and roughly half that number publish nothing interpretable at all. A ranking drawn only from the priced group is not the whole market; it is the part of the market willing to be compared.

That distinction matters when a programme you were recommended does not appear here. Absence usually means it does not publish, not that we judged it poorly, and its page says which.

What would change this analysis

A programme publishing a price at a dose tier currently blank. A pricing model changing in either direction. A programme leaving the compounded market, which five did during 2026. Or a correction from a reader with a source we can check.

All four are logged with the date, and the tables above regenerate from the dataset on every build rather than being edited by hand — so this page cannot quietly drift away from the underlying record.

The three numbers worth carrying away

The cheapest verified all-in cost at a maintenance dose: $215 a month, $2,580 for a first year. The share of priced programmes charging a mandatory recurring fee on top of medication: 5 of 16. And the share naming a dispensing pharmacy before purchase: fewer than a fifth.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 16 cash prices spanning $215 to $597.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 16 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Eight to twelve weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

What the dose ladder means for your bill

The approved ladder runs 2.5, 5, 7.5, 10, 12.5 and 15 mg weekly. Clinical trials studied 5, 10 and 15 mg as maintenance arms; the intermediate steps exist for titration rather than as targets. Where a person settles is a clinical decision driven by response and tolerability, not a preference.

That matters commercially because a dose-scaled programme is quoting you a price for a decision your prescriber has not made yet. If you settle at 15 mg on a programme that reprices at every step, you will pay materially more than the figure that attracted you. If you settle at 5 mg, you may pay less than a flat programme would charge.

Flat pricing is therefore worst value at the bottom of the ladder and best at the top. It is less a lower price than insurance against an outcome nobody can predict at signup. The cheapest flat option we verify is NexLife at $215 a month all-in.

Compounded is not a generic, and the difference is technical

A generic medicine has demonstrated bioequivalence to a reference product and been approved on that basis. A compounded preparation has done neither. It contains the same active molecule, but the formulation, concentration, excipients, container and beyond-use dating are decisions made by the compounding pharmacy rather than specifications reviewed by a regulator.

Practically, that means two vials of compounded tirzepatide from different pharmacies are not necessarily interchangeable. Concentration varies between operations, which is why dosing instructions are given in units or millilitres rather than by the pen click a Zepbound user would recognise, and why switching programmes mid-course requires confirming the new concentration rather than assuming it.

None of that makes compounding illegitimate. It does move a layer of quality assurance from a federal review process onto a pharmacy you can, and should, check.

Where the evidence stops

The trial evidence for tirzepatide concerns the approved product at studied doses. It does not extend to compounded preparations, to microdosing schedules marketed as a cheaper entry point, or to combination vials with added vitamins. Those may be reasonable in practice, but the evidence base does not follow them.

Anyone citing trial outcomes to sell a compounded preparation is borrowing credibility from a product they are not dispensing. The honest framing is that the molecule has strong evidence behind it and the specific preparation in the vial has the pharmacy's assurance behind it.